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ABSTRACT 
Objective: The present study attempted to evaluate the anti-biofilm activity of D-amino acids (D-AAs) on Pseudomonas aeruginosa and determine if 
the combination of D-AAs with tetracycline enhances the anti-biofilm activity in vitro and ex vivo. 
Methods: Different D-AAs were tested for antibiofilm activity against wild type P. aeruginosa PAO1 and two multidrug resistant P. aeruginosa 
clinical strains in the presence of sub inhibitory concentrations of tetracycline using crystal violet microtitre plate assay. Results were further 
validated using in vitro wound dressing and ex vivo porcine skin models followed by cytotoxicity and hemocompatibility studies. 
Results: D-tryptophan (5 mmol) showed 61 % reduction in biofilm formation of P. aeruginosa. Interestingly combinatorial effect of 5 mmol D-
tryptophan and 0.5 minimum inhibitory concentration (MIC) (7.5µg/ml) tetracycline showed 90% reduction in biofilm formation. 5 mmol D-
methionine shows 28 % reduction and combination with tetracycline shows 41% reduction in biofilm formation of P. aeruginosa. D-leucine and D-
tyrosine alone or in combination with tetracycline did not show significant anti-biofilm activity. D tryptophan-tetracycline combination could 
reduce 80 % and 77 % reduction in biofilm formation in two multi drug resistant P. aeruginosa clinical strains. D-tryptophan-tetracycline-
combination could also reduce 76% and 66% reduction in biofilm formation in wound dressing model and porcine skin explant respectively. The 
cytotoxicity and hemocompatibility studies did not show significant toxicity when this combination was used.  
Conclusion: The results established the potential therapeutic application of D-tryptophan alone or in combination with tetracycline for treating 
biofilm associated clinical problems caused by P. aeruginosa. 
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Many bacteria form biofilm, which is 
Classically biofilm development can be divided into three events, 
attachment, maturation and dispersion [5, 6]. 
an assemblage of surface-
associated microbial cells enclosed in an extracellular polymeric 
substance matrix. Biofilm, which consists of polysaccharide, protein and 
DNA [1] has high significance in agricultural, industrial, environmental 
and clinical settings. The soil bacterium, Bacillus subtilis forms biofilm on 
the roots to protect plants from variety of pathogens [2]. The cause of 
most of the persistent infections is biofilm formation, as these groups can 
tolerate very high doses of antibiotics that would kill planktonic cells. P. 
aeruginosa, the most predominant pathogen in immuno-compromised 
patients [3, 4] forms biofilm virtually on any surface at any nutritional or 
environmental conditions. The ability to form biofilm is thought to be 
one of its main survival strategies when infecting a host and it is 
considered to be important for pathogenesis [1]. 
The final event contributes 
to biological dispersal, bacterial survival, and disease transmission. I
MATERIALS AND METHODS 
t 
provides a mechanism whereby biofilm bacteria can spread throughout 
an infected organ [7] or to the whole body, in which a chronic infection 
can cause an acute blood stream infection [8-10]. Bacterial detachment 
and dispersal are triggered by various chemical signals [7]. Some of them 
are D-AAs, lysostaphin, farnesol, and cis-2-decenoic acid [11]. Given that 
many bacteria produce D-AAs, these molecules may provide a general 
strategy for biofilm disassembly [12]. Combining biofilm dispersal and 
inhibition agents with antibiotics can greatly enhance the susceptibility 
of bacterial biofilm to antibiotic therapy [13]. D-AAs such as D-
tryptophan reported to have inhibitory effect on biofilm development by 
food borne organism Cronobacter sakazakii.[14]. Similarly combination 
of D-tyrosine with tetrakishydroxymethyl phosphonium sulphate has 
the ability to mitigate sulfur reducing bacterial biofilm[15]. In addition to 
biofilm inhibitory properties D-AAs also have other properties. 
Administration of D-methionine after noise exposure leads to rescue 
from noise induced auditory brain stem response threshold shift [16]. D-
leucine has potential anti-seizure properties. [17]. In the present study 
we evaluated the combinatorial effect of D-AAs with antibiotics. The 
antibiofilm activities of the tetracycline and D-AAs combination against 
P. aeruginosa strains were tested. 
Bacterial strains and treatments 
P. aeruginosa wild strain, PAO1 (P. aeruginosa ATCC 15692) obtained 
from ATCC and two multidrug resistant clinical strains PACL-W (P. 
aeruginosa clinical strain-surgical wound swab(leg) and PACL-S (P. 
aeruginosa clinical strain-sputum) were treated with amino acids, D-
leucine, D-tryptophan, D-methionine and D-tyrosine (Sigma Aldrich, 
USA). All the other aminoacids except D-tyrosine was dissolved in 
distilled water and D-tyrosine was dissolved in 1N HCl. 
Antibiotic sensitivity of bacterial strains was assessed by disc diffusion 
method. Antibiotic discs (Himedia India) were placed on the surface of 
Müeller Hinton agar plates (Himedia, India). Subsequent to overnight 
incubation at 37 °C, growth inhibition zones formed around the disks 
were measured. The minimum inhibitory concentration (MIC) was 
evaluated by broth dilution method. Briefly, bacterial suspensions were 
prepared in 0.9% saline from overnight cultures and adjusted to attain 
the 0.5 McFarland turbidity standards. Suspensions were inoculated 
onto Müeller-Hinton broth containing antibiotics at concentrations 5-50 
µg/ml and incubated at 37 °C for 20 to 24 h [18]. 
Determination of biofilm formation 
Biofilm formation was assessed by microtiter plate method [19]. 
Briefly, overnight bacterial cultures were diluted to 0.1 OD at 600 
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nm.100 µl of diluted sample was incubated with D-AAs and 0.5 MIC 
tetracycline combination in culture medium (LB broth) at 37 °C for 
24 h in 96-well polystyrene micro titer flat bottom plate (Nest 
Biotech Co. Ltd). After incubation, the medium was discarded; wells 
were washed with water and incubated with crystal violet (0.1%) 
for 10 min. Subsequently the plates were washed with water to 
remove the unbound dye. The crystal violet bound to the biofilm was 
eluted using 33% acetic acid and optical density (OD) was recorded 
at 600 nm using a Synergy HT Multi-Mode Microplate Reader 
(BioTek Instruments, Winooski, VT). Percentage inhibition of biofilm 
formation was calculated using the following formula 
% inhibition =
OD of Control− OD of test
OD of Control
∗ 100 
Cell viability assay 
Cell viability assay was performed according to the protocol described 
earlier [20]. 3T3-L1 mouse fibroblast cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 % foetal 
bovine serum (FBS) (v/v), 1% penicillin, 1% streptomycin and 0.1% 
amphotericin B. Cell viability assays were performed for cells treated 
with/without D-tryptophan in DMEM by using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). 3T3-L1 cells 
were seeded at a density of 7500 cells/well in a 96-well microtiter plate 
and incubated overnight. Cells were treated with and without D-
Tryptophan at a concentration of 5 mmol and 10 mmol in DMEM for 24 
h. 20 µl of 5 mg/ml MTT was added to each well and incubated for 3 h at 
37 °C. The media was removed after incubation and 100 µl of MTT 
solvent (4 mmol HCl and 0.1% Nonidet P-40 in isopropanol) was added 
for solubilisation. After shaking briefly for 5 min, the absorbance was 
read at 590 nm with a reference filter of 620 nm using a Synergy HT 
Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT). 
Determination of hemolysis 
Extent of hemolysis was determined according to previously described 
method [21]. Briefly 1 ml blood was diluted 10 times with Ringer buffer. 
200 µl of diluted blood was incubated with D-tryptophan and 
tetracycline at 37 °C for 24 h and centrifuged at 3,500 rpm for 15 min. 
OD of the supernatant was recorded at 540 nm using microplate reader. 
Triton-X 100 (0.01%) and 0.9 % saline treated blood samples served as 
positive and negative controls respectively.  
In vitro wound dressing model 
The in vitro wound dressing model was done as previously described 
[22]. Overnight bacterial cultures were diluted in fresh LB broth to 
contain 1x108colony forming units (CFU)/ml and placed on sterile 
polyethylene absorbent wound dressing (1.5 cm x 1.5 cm) in freshly 
prepared LB agar plates. The plates were kept undisturbed for 30 min 
while the inoculum was allowed to dry. Fresh gauze squares (2 cm x 2 
cm) with D-tryptophan and tetracycline were placed over the inoculated 
polyethylene pads and the plates were incubated at 37 °C. After 24 h of 
growth period, the samples were removed from the plates and the 
polyethylene pads or gauze pieces were separated and processed to 
determine the biofilm formation. Polyethylene pads were washed with 
normal saline and vortexed in saline for 1 min. The bacterial suspension 
was then serially diluted and 1 ml aliquots of each dilution were placed 
on LB agar plates. After 24 h of incubation at 37 °C, the colony forming 
units were calculated. 
Ex-vivo porcine skin model 
Ex-vivo porcine skin model was prepared according to the protocol 
described earlier [21, 23]. Hides from carcasses of freshly killed 
adult pigs obtained from a local slaughter house were thoroughly 
washed and de-haired. The excess fat deposits were removed and 
cut into sections of 2 cm × 2 cm. Subsequently the skin explants 
were washed in PBS, disinfected with 70 % ethanol for 5 min and 
allowed to dry in sterile petri plates. The explants were incubated at 
37 °C for 24 h with 100 µl bacterial suspension with/without test 
compounds. They were submerged in Tryptic soy broth. After 
incubation; sections were rinsed with sterile PBS to remove the 
unattached bacterial cells. Subsequently the sections were 
aseptically transferred to sterile test tubes containing sterile PBS 
with 5 µl/l Tween 80 and sonicated to liberate bacteria from the 
biofilm. This suspension was then serially diluted and 100 µl 
aliquots of each dilution were spread on Tryptic Soy agar (TSA). 
After overnight incubation at 37 °C, the colonies were counted and 
the colony forming unit (CFU) was calculated. 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism software. 
Values are expressed as mean±SD. Dunnett-ANOVA test was 
employed to compare between the test and control. Significance at 
*p<0.05 Vs control, **p<0.01 Vs control, ***p<0.001. Vs control 
RESULTS 
Antibiotic susceptibility and minimum inhibitory concentration 
(MIC) 
Antibiotic susceptibility was tested using ciprofloxacin, ceftazidime, 
amikacin, co-trimoxazole, gentamycin, streptomycin, chloramphenicol 
and tetracycline. All the three P. aeruginosa strains were susceptible to 
tetracycline. The lowest concentration of tetracycline which inhibits the 
visible growth of bacterium i.e. the MIC value was found to be 15µg/ml. 
Hence sub inhibitory concentration (0.5MIC) i.e. 7.5 µg/ml of 
tetracycline was selected for further experiments. The results of MIC of 
tetracycline is shown in fig. 1. 
 
 
Fig. 1: Minimum inhibitory concentration (MIC) of tetracycline. 
MIC of tetracycline against P. aeruginosa was determined at a 
concentration range from 5-50 µg/ml. Mean values of triplicate 
independent experiments and SD is shown. Dunnett's test 
demonstrates significant difference between the tests and the 
control. Significance at ***p<0.001 
 
Dose dependent effect of D-AAs and D-AAs-tetracycline 
combination on biofilm formation of P. aeruginosa 
To evaluate the potential of D-AAs and a combination of D-AAs with 
tetracycline on antibiofilm activity against P. aeruginosa PAO1, different 
doses of D-AAs ranging from 5-50 mmol in combination with 0.5 MIC 
tetracycline (7.5µg/ml) were selected for testing.(fig. 2 (A). As shown in 
fig. 2 (B) among the four D-AAs tested D-tryptophan showed maximum 
antibiofilm activity at 5 mmol (61%), while D-tryptophan-tetracycline 
treatment showed 90% inhibition. 5 mmol D-methionine showed 28 % 
inhibition and combination with tetracycline augmented the effect to 
41%. In contrast, D-leucine and D-tyrosine had minimal antibiofilm 
activity even at a concentration of 50 mmol. 
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Fig. 2: (A). Dose-dependent effect of D-AAs against P. aeruginosa 
biofilm formation. Screening of antibiofilm activity of individual 
D-AAs, D-methionine, D-tyrosine, D-tryptophan and D-leucine 
at concentrations ranging from 5 mmol to 50 mmol and its 
combination with 0.5 MIC tetracycline (7.5 µg/ml) (Tet). Mean 
values of triplicate independent experiments and SD are shown. 
Dunnett's test demonstrates significant difference between the 
tests and the control. Significance at *p<0.05, **p<0.01, 
***p<0.001, (B). Percentage inhibition of biofilm formation by P. 
aeruginosa PAO1 with different D-aminoacids (5 mmol) and its 
combination with 0.5 MIC (7.5 µg/ml) tetracycline (T) 
D-tryptophan-tetracycline combination disperses the biofilm 
formed by clinical isolates of P. aeruginosa 
Treatment with 5 mmol D-tryptophan-0.5 MIC tetracycline 
combination on multi-drug resistant P. aeruginosa strains PACL-S (P. 
aeruginosa clinical strain-sputum) and PACL-W (P. aeruginosa 
clinical strain-leg wound swab) demonstrated significant anti 
biofilm activity. This activity of D-AAs against biofilm was partly 
strain dependent. Treatment with 5 mmol tryptophan inhibited 
biofilm formation in PACLW and PACLS by 51% and 50.5 % 
respectively, while treatment with D-tryptophan and tetracycline in 
combination augmented this effect by 80 % and 77 % respectively in 
PACLW and PACLS (fig. 3). 
 
 
Fig. 3: Percentage inhibition of the biofilm formed by clinical 
strains of P. aeruginosa. P. aeruginosa strains isolated from 
sputum (PACL-S) and wound (PACL-W) treated with 5 mmol 
tryptophan (Trp) alone or in combination with 0.5 MIC 
tetracycline (Tet). Mean values of triplicate independent 
experiments and SD are shown 
 
In vitro wound dressing model and ex-vivo porcine skin model 
To better understand anti-biofilm activity of D-tryptophan-
tetracycline combination in other biofilm models, we used in vitro 
wound dressing and ex-vivo porcine skin models. In wound dressing 
model, 5 mmol D-tryptophan in combination with 0.5 MIC 
tetracycline reduced biofilm formation (76%) when compared to 
controls (fig. 4). 
 
 
Fig. 4: Effect of D-tryptophan and 0.5 MIC tetracycline 
combination on the biofilm formed by P. aeruginosa using in 
vitro wound dress model and ex vivo porcine skin model. 
Wound dress/porcine skin inoculated with bacterial cultures 
were treated with 5 mmol tryptophan and 0.5 MIC tetracycline. 
Planktonic bacteria were removed and the bacteria present in 
the biofilm were detected by plated into LB agar plates. Mean 
values of triplicate independent experiments and SD are shown 
 
Further, the anti-biofilm activity of 5 mmol D-tryptophan in 
combination with 0.5 MIC tetracycline was tested using ex-vivo 
porcine skin model. Consistent with the previous result, D-
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tryptophan in combination with tetracycline inhibited biofilm 
formation in porcine skin explants by 66% compared to the 
untreated explants (fig. 4). These results confirm the efficacy of D-
tryptophan-tetracycline combination in inhibiting biofilm 
formation. 
Cell viability assay 
To investigate the effect of D-tryptophan on viability of cells, MTT 
assay was performed.3T3-L1 fibroblast cells were incubated with 5 
mmol and 10 mmol D-tryptophan with/without 0.5 MIC tetracycline 
for 24 h. Results from MTT analysis showed no significant 




Fig. 5: Effect of D-tryptophan in combination with 0.5 MIC 
tetracycline on cell viability of 3T3-L1 fibroblast cells. Cell 
viability using MTT cytotoxicity assay was performed for the 
3T3-L1 cells treated with D-tryptophan in combination with 0.5 
MIC tetracycline in DMEM supplemented with 10% FBS. Mean 
values of triplicate independent experiments and SD are shown. 
Dunnett's test demonstrates no significant difference between 
the test and the control 
 
Hemocompatibility testing of D-tryptophan in combination with 
tetracycline 
The hemocompatibility of 5 mmol D-tryptophan-0.5 MIC tetracycline 
mixture was analyzed. No significant hemolysis was observed when 
this combination was used (fig. 6). 
 
 
Fig. 6: Hemocompatibility of D-Tryptophan in combination with 
0.5 MIC tetracycline (Tet). A representative bar diagram 
showing hemolysis by Triton X 100, normal saline, 0.5 MIC 
tetracycline, 5 mmol tryptophan and 5 mmol tryptophan-0.5 
MIC tetracycline combination. Mean values of triplicate 
independent experiments and SD are shown. Dunnett's test 
establishes significant difference between the test and the 
control. Significance at ***p<0.001 Vs control 
DISCUSSION 
Most of the commercially available antibiotics are developed against 
planktonic and metabolically active bacteria. However, bacteria in 
the biofilm are different and can be 10-1,000 times more resistant to 
antibiotics than planktonic bacteria [24]. Designing an anti-biofilm 
strategy is complicated due to the characteristic properties 
possessed by biofilm [25] that include protective shielding by the 
matrix, specific expression of microbial proteins for nutrient 
scavenging, ramping down of metabolic activity, induction of a 
secluded state in which bacterial cells are in a phenotypically 
variable state and resistant to antimicrobial treatment [26, 27]. 
Recent studies have pointed out the possible use of antibiofilm/biofilm 
dispersing agents like D-AAs as potential therapeutic molecules [12]. 
Combining these agents with antibiotics can have significant 
promising effects. In Bacillus subtilis, a mixture of D-AAs (D-leucine, D-
methionine, D-tyrosine and D-tryptophan) is reported to prevent 
biofilm formation and induce existing biofilm disassembly [11]. 
Previous studies have reported anti-biofilm activities of D-AAs in 
Staphylococcus aureus [12] and P. aeruginosa [13]. These results 
indicate that D-AAs might prove widely useful in medical and 
industrial applications for the prevention or eradication of biofilm.  
Consistent with previous studies [13], D-tryptophan showed highest 
antibiofilm activity followed by D-methionine, while marginal 
activity was observed in the case of D-leucine and D-tyrosine. A dose 
dependent antibiofilm activity was seen in the presence of D-
tryptophan. Although tetracycline alone did not show any significant 
activity against biofilm at 0.5 MIC, combination of tetracycline and 
D-AAs showed enhanced antibiofilm activity. We also observed that 
co-treatment of D-tryptophan-tetracycline had promising 
antibiofilm effect compared to other combinations. Our results are in 
line with previous studies that have demonstrated that the activity 
of various antimicrobial agents can be significantly enhanced by the 
addition of dispersal agents [28]. 
As a model designed to assess the efficacy of topical application of 
tetracycline and D-tryptophan combination, gauze squares saturated 
with this combination was checked for their antibiofilm activity. The 
decreased bacterial load recovered from the dressing containing 5 
mmol D-tryptophan-0.5 MIC tetracycline mixture when compared to 
the untreated control supported the observations from the biofilm 
tests done in microtitre plate. Further, the antibiofilm activity of D-
tryptophan-tetracycline combination was validated using porcine 
skin infection model. Porcine skin model for bacterial biofilm 
attachment was selected because it fulfills the requirements of an ex 
vivo model due to its similarity with human skin physiology. The 
other advantage of using such a model is that a large number of 
trials can be conducted economically [23]. Our study clearly 
elucidated that a single application of 5 mmol D-tryptophan-0.5 MIC 
tetracycline combination was capable of reducing P. aeruginosa 
biofilm attachment to porcine skin explants. Cell viability assay 
performed in 3T3-L1 fibroblast cells showed that 5 mmol and 10 
mmol D tryptophan in combination with 0.5 MIC tetracycline did not 
have any cytotoxic effect. The results of hemocompatibility studies 
were also in strong agreement with the cytotoxicity studies 
suggesting the potential of D-tryptophan-tetracycline combination 
as an effective therapy against P. aeruginosa infections. 
The mechanism through which the D-AAs and its combination with 
antimicrobials act against biofilm have not been fully addressed yet. It 
is possible that D-AAs cause altered protein expression, disrupt cell 
wall integrity and metabolic status. A recent study reported that 
epigallocatechin gallate,the major catechin present in green tea extract 
enhances tetracycline activity against resistant staphylococcal isolates 
by impairment of tetracycline efflux pump activity thereby increasing 
intracellular retention of the drug leading to effective synergistic drug 
combination [29, 30]. The results obtained demonstrate that antibiotic 
treatment with D-AAs could be more effective to reduce infections 
with minimal systemic toxicity. Moreover antibiotic concentrations 
required could be reduced by co-delivery with D-AAs, by which 
antibiotic toxicity can potentially reduced.  
CONCLUSION 
In conclusion, we have demonstrated in vitro anti-biofilm activity by 
D-AAs in P. aeruginosa. Anti-biofilm activity by individual amino 
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acids was dose dependent, and amino acids in combination with 
tetracycline potentiated the anti-biofilm activity against diverse 
isolates of P. aeruginosa. The in vitro studies were validated using ex 
vivo porcine skin model. This combination may find commercial 
advantages in topical applications and treatment of infections 
caused by P. aeruginosa. 
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